Which generation of targeted drug is Brigatinib/Brigatinib?

Brigatinib/Brigatinib (Brigatinib) is a second-generation targeted drug used to treat non-small cell lung cancer (NSCLC). Below I will introduce in detail the characteristics, uses and development of brigatinib/brigatinib as a second-generation targeted drug.

The second generation of targeted drugs is relative to the first generation of targeted drugs, which include erlotinib (Erlotinib) and gefitinib (Gefitinib), which mainly act on the epidermal growth factor receptor (EGFR) on tumor cells. However, the therapeutic efficacy of first-generation targeted drugs may be limited due to the existence of certain resistance mechanisms. Therefore, the development of second-generation targeted drugs aims to overcome these resistance mechanisms and provide better therapeutic effects.

Brigatinib/Brigatinib is one of the representatives of the second generation of targeted drugs. It is approved to treat ALK (ALK) rearranged NSCLC, a common subtype of lung cancer. Brigatinib/The mechanism of action of Brigatinib is to inhibit the ALK fusion protein and block cell signaling, thereby inhibiting tumor growth and spread.

CurrentlyBrigatinib/Brigatinib has been marketed in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy, but the price is quite high, more than 10,000 yuan. Overseas Brigatinib/Brigatinib are mainly generic drugs, mainly from Bangladesh and Laos. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, specification: 90mg*30 tablets; the price of Laos version of generic drugs is about About 600, and the specifications are less. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.